Bulk Pharmaceutical API Sources for sevoflurane

Bulk Pharmaceutical API Sources for sevoflurane

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		F0691
Molport		MolPort-001-775-746
Hangzhou APIChem Technology		AC-15484
Amadis Chemical		A819479
AKos Consulting & Solutions		AKOS007930500
TimTec		SBB092545

SEVOFLURANE BULK ACTIVE PHARMACEUTICAL INGREDIENT SOURCES

Last updated: February 19, 2026

This report identifies key manufacturers and supply chain considerations for bulk Sevoflurane active pharmaceutical ingredient (API). The analysis focuses on production capacity, regulatory standing, and geographic distribution of API suppliers to inform strategic sourcing and investment decisions.

What is Sevoflurane API?

Sevoflurane is a volatile anesthetic agent used for the induction and maintenance of general anesthesia. Its chemical name is 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane. The bulk API is the raw material prior to formulation into the final injectable or inhalable drug product.

Global Sevoflurane API Production Landscape

The production of Sevoflurane API is concentrated among a limited number of global manufacturers. Key players are located in Asia and Europe, with some having vertically integrated operations that include intermediate synthesis.

Major Sevoflurane API Manufacturers

Manufacturer Name	Primary Location	Key Product Focus	Regulatory Approvals (Examples)	Notes
AbbVie Inc. (formerly Abbott Laboratories)	United States	Sevoflurane API and finished drug product	US FDA, EMA	Long-standing market presence.
Baxter International Inc.	United States	Sevoflurane API and finished drug product	US FDA, EMA	Significant global distributor.
Piramal Pharma Solutions	India	Contract Development and Manufacturing Organization (CDMO) for APIs	US FDA, EMA, PMDA	Offers custom synthesis services.
Cosmo Technologies Ltd.	India	Sevoflurane API	US FDA, EMA	Focus on high-purity API.
Jiangsu Hengrui Medicine Co., Ltd.	China	Sevoflurane API	NMPA, US FDA (pending/in progress)	Expanding API production capacity.
Zhejiang NHU Co., Ltd.	China	Sevoflurane API	NMPA, US FDA (pending/in progress)	Diversified chemical manufacturer.
Shandong Luxi Chemical Group Co., Ltd.	China	Sevoflurane API	NMPA	Large-scale chemical producer.
Loba Chemie Pvt. Ltd.	India	Sevoflurane API	Various national agencies	Supplier to research and industrial markets.
Haltermann Carless	Germany	Specialty chemicals, including fluorinated compounds	REACH	Focus on high-purity solvents and intermediates.

Geographic Concentration of API Supply

The majority of bulk Sevoflurane API production is located in two key regions:

• Asia (primarily India and China): These regions host several large-scale chemical manufacturers and CDMOs that have established significant production capacity for Sevoflurane API. Factors contributing to this concentration include lower manufacturing costs, established chemical infrastructure, and increasing regulatory compliance.
• North America and Europe: While some major pharmaceutical companies maintain API production or have legacy supply agreements in these regions, newer capacity is predominantly emerging from Asia. These established players often hold key regulatory approvals and may represent a stable, albeit potentially higher-cost, supply option.

Regulatory Considerations for Sevoflurane API

Compliance with stringent regulatory standards is paramount for Sevoflurane API suppliers. This includes Good Manufacturing Practices (GMP), Drug Master Files (DMFs), and adherence to pharmacopeial standards.

Key Regulatory Bodies and Requirements

• U.S. Food and Drug Administration (FDA): Requires API manufacturers supplying the U.S. market to comply with current GMP (cGMP). Manufacturers typically submit a Type II DMF to detail the manufacturing process, facilities, and controls.
• European Medicines Agency (EMA): Manufacturers must adhere to EU GMP standards. A European Drug Master File (EDMF) or equivalent documentation is required.
• Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Japanese GMP standards apply, with DMF submissions mandated.
• National Medical Products Administration (NMPA) China: Requires compliance with Chinese GMP and DMF filings.
• Pharmacopeial Standards: API must meet specifications outlined in the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards cover identity, purity, assay, and impurity limits.

Impact of Regulatory Approvals on Supply Chain Security

• FDA and EMA Approval: Suppliers with established FDA and EMA approvals represent a lower regulatory risk for finished drug product manufacturers. The time and investment required to obtain and maintain these approvals can act as a barrier to entry for new API producers.
• DMF Status: A complete and up-to-date DMF is crucial. It allows finished drug product manufacturers to reference the API supplier's manufacturing information in their own drug applications without disclosing proprietary details. Any deficiencies or holds on a DMF can disrupt supply.
• Inspections: Regular inspections by regulatory agencies verify ongoing GMP compliance. Past inspection records, including any Form 483 observations or warning letters, can indicate potential supply chain vulnerabilities.

Supply Chain Dynamics and Risk Factors

The Sevoflurane API supply chain is characterized by specific dynamics and potential risk factors that impact pricing, availability, and quality.

Pricing Influences

• Raw Material Costs: The synthesis of Sevoflurane involves fluorinated intermediates and other specialty chemicals. Fluctuations in the price and availability of these precursors directly impact API production costs.
• Manufacturing Scale and Efficiency: Larger production volumes generally lead to lower per-unit costs due to economies of scale. Highly automated and efficient manufacturing processes also contribute to cost competitiveness.
• Regulatory Compliance Costs: Meeting stringent GMP and environmental regulations incurs significant costs, which are passed on to buyers.
• Geopolitical Factors: Trade policies, tariffs, and political instability in key manufacturing regions can affect raw material sourcing and final API pricing.
• Competition: The number of qualified suppliers and their respective capacities influence market pricing. A limited supplier base can lead to higher prices.

Key Risk Factors

• Single-Sourcing Dependence: Relying on a single API supplier, even if approved, introduces significant risk. Any disruption at that supplier's facility (e.g., quality issues, production shutdowns, regulatory actions, natural disasters) can halt finished drug product manufacturing.
• Quality Control and Impurity Profiles: Variations in manufacturing processes can lead to different impurity profiles. Changes in an API supplier's process, even if within regulatory limits, may require revalidation by the finished drug product manufacturer. Ensuring consistent quality and controlling potential genotoxic impurities is critical.
• Geographic Concentration: Over-reliance on suppliers from a single geographic region increases vulnerability to regional disruptions, such as pandemics, political unrest, or natural disasters.
• Intellectual Property and Patent Landscape: While the primary patents for Sevoflurane have expired, process patents related to API synthesis and purification can still influence manufacturing methods and market exclusivity for certain producers.
• Logistics and Transportation: Global supply chains are susceptible to disruptions in shipping, air freight, and customs clearance, especially for temperature-sensitive or hazardous materials.

Strategic Sourcing and Due Diligence

Effective sourcing of Sevoflurane API requires a multi-faceted approach to mitigate risks and ensure a stable supply of quality material.

Steps for Strategic Sourcing

1. Supplier Qualification:
   • Regulatory Status: Verify current GMP certifications, DMF filings, and inspection histories with relevant regulatory bodies (FDA, EMA, etc.).
   • Technical Capabilities: Assess manufacturing capacity, process control, analytical testing capabilities, and experience with fluorinated compounds.
   • Quality Management System (QMS): Review the supplier's QMS, including change control procedures, deviation management, and batch release processes.
   • Financial Stability: Evaluate the financial health of potential suppliers to ensure long-term viability.
2. Dual Sourcing Strategy: Identify and qualify at least two independent API suppliers with different geographic footprints and manufacturing processes to reduce single-sourcing risk.
3. Auditing: Conduct thorough on-site audits of qualified suppliers to verify their manufacturing operations, quality systems, and compliance with stated procedures.
4. Contractual Agreements: Establish robust supply agreements that clearly define quality specifications, lead times, pricing mechanisms, change control notification protocols, and force majeure clauses.
5. Inventory Management: Maintain appropriate buffer stock of API and critical raw materials to manage supply chain lead times and potential disruptions.
6. Continuous Monitoring: Regularly monitor supplier performance, regulatory updates, and market dynamics to proactively address emerging risks.

Due Diligence Checklist

• Current GMP Certification: Is the supplier's facility currently certified and inspected by relevant regulatory authorities?
• DMF Status: Is the DMF complete, up-to-date, and free from deficiencies?
• Auditable History: Does the supplier have a history of successful regulatory inspections?
• Capacity and Redundancy: Does the supplier have sufficient capacity to meet demand, and do they have backup manufacturing sites or processes?
• Traceability: Can the supplier trace all raw materials and intermediates used in production?
• Environmental and Safety Compliance: Does the supplier adhere to environmental and safety regulations relevant to chemical manufacturing?
• Business Continuity Plan: Does the supplier have a documented plan for business continuity in case of disruptions?

Future Outlook for Sevoflurane API Supply

The demand for Sevoflurane API is expected to remain stable, driven by its established position in anesthesia. However, the supply landscape may evolve due to several factors:

• Increasing Competition from Asian Manufacturers: As Chinese and Indian manufacturers continue to invest in quality systems and gain regulatory approvals, they are likely to increase their market share.
• Focus on Green Chemistry and Sustainability: Growing emphasis on environmentally friendly manufacturing processes may drive innovation in Sevoflurane synthesis, potentially favoring suppliers with advanced sustainable practices.
• Consolidation in the API Market: Mergers and acquisitions within the CDMO and API manufacturing sectors could alter the competitive landscape.
• Technological Advancements: New synthesis routes or purification technologies could emerge, offering cost advantages or improved purity profiles, thereby shifting competitive dynamics.

Key Takeaways

• Sevoflurane API production is concentrated in Asia and Europe, with key manufacturers including AbbVie, Baxter, Piramal Pharma Solutions, Cosmo Technologies, and several Chinese chemical conglomerates.
• Regulatory compliance with US FDA, EMA, and other national agencies is critical, with DMF filings serving as a cornerstone of the supply chain.
• Supply chain risks are significant and include dependence on single suppliers, geographic concentration, quality control variations, and logistical challenges.
• Strategic sourcing necessitates robust supplier qualification, dual sourcing strategies, comprehensive auditing, and strong contractual agreements.
• The future market will likely see increased competition from Asian suppliers and a growing emphasis on sustainable manufacturing practices.

Frequently Asked Questions

1. What are the primary impurities to monitor in Sevoflurane API? Primary impurities that require monitoring include related substances such as desflurane, isoflurane, and various degradation products arising from hydrolysis or thermal decomposition. Specific genotoxic impurities must also be rigorously controlled below acceptable limits as per ICH guidelines.

2. How long does it typically take for a new Sevoflurane API supplier to become qualified by a finished drug product manufacturer? The qualification process for a new API supplier can range from 6 to 18 months. This timeframe accounts for initial supplier assessment, technical data review, on-site audits, quality agreement finalization, and sample testing by the finished drug product manufacturer, followed by batch validation studies.

3. What is the typical shelf life of bulk Sevoflurane API? The typical shelf life of bulk Sevoflurane API is generally between 18 to 36 months when stored under recommended conditions (e.g., in tightly sealed containers, protected from light and moisture, at controlled room temperature). Specific shelf life is determined by stability studies and defined by the manufacturer.

4. Are there any known geopolitical risks currently impacting Sevoflurane API supply? Geopolitical risks can arise from trade disputes, tariffs, or regional instability in countries where raw materials for Sevoflurane synthesis are sourced or where API manufacturing is concentrated. Current impacts are dynamic and depend on ongoing international relations and regulatory policy shifts.

5. Can Sevoflurane API be manufactured using green chemistry principles? Yes, advancements in synthetic chemistry are leading to the development of greener routes for fluorinated compounds, including Sevoflurane. This may involve using less hazardous solvents, optimizing reaction conditions to reduce waste, and employing more energy-efficient processes, though widespread adoption varies among manufacturers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files-dmfs

[2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-active-substance-master-file-procedure-scientific-guideline_en.pdf

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. Retrieved from https://www.ich.org/page/quality-guidelines

[4] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from https://www.usp.org/pharmacopeial-forum

[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certification of suitability to the European Pharmacopoeia monographs (CEP). Retrieved from https://www.edqm.eu/en/certification-suitability-european-pharmacopoeia-monographs-cep